Skip to main content
Premium Trial:

Request an Annual Quote

Nutromics Raises $14M in Pre-Series A Funding Round

NEW YORK – Australian health technology startup Nutromics said on Thursday that it has raised $14 million in its pre-Series A funding round, bringing the company's money raised to date to over $20 million.

Investors in this round included Dexcom Ventures, VU Venture Partners, and Artesian Investments, Nutromics said, and the funding will support the expansion of clinical studies, R&D team, and investment across both its Australian and US hubs.

Established in 2017, Nutromics, now with offices in Brunswick, Victoria, and San Diego, is using an electrochemical DNA aptamer-based sensor technology licensed from the University of California, Santa Barbara to develop a noninvasive, continuous molecular monitoring medical device that it initially hopes to enable applications such as antibiotic monitoring. Earlier this year, it appointed former Abbott Laboratories Senior Medical Director Agim Beshiri as its inaugural chief medical officer.

The company said it "plans to raise significantly more funding in 2023 following in vivo clinical studies."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.